![]() Ionis Pharmaceuticals Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics. | ![]() Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. | ![]() Reata Pharmaceuticals Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases. | ![]() Alnylam Pharmaceuticals Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. | ![]() Ultragenyx Pharmaceutical Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases. | ![]() Intellia Therapeutics Intellia is developing therapeutic products to help people with genetic diseases. | ![]() Sarepta Therapeutics Sarepta Therapeutics is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapeutics, gene therapy and, other genetic therapeutic modalities for the treatment of rare diseases. | |||
Founding Date | Founding Date 1989 | Founding Date 1992 | Founding Date 2004 | Founding Date 2002 | Founding Date 2002 | Founding Date 2010 | Founding Date 1942 | Founding Date 2014 | Founding Date 1980 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||||||
Locations | Locations Carlsbad, US HQ | Locations Pasadena, US HQ Madison, US San Diego, US | Locations Plano, US HQ Irving, US Plano, US | Locations Novato, US HQ | Locations Trevose, US HQ Philadelphia, US | Locations Cambridge, US HQ | Locations Cambridge, US HQ Dublin, IE Zug, CH Providence, US | ||
Employees | Employees 7577% decrease | Employees 1,2134% increase | Employees 13416% increase | Employees 22079% increase | Employees 1,32324% increase | Employees 74021% increase | Employees 81015% decrease | Employees 27028% increase | Employees 8403% decrease |
Valuation ($) | Valuation ($) 6.8 b | Valuation ($) 324.1 m | Valuation ($) 3.3 b | Valuation ($) 6.5 b | Valuation ($) 21.9 b | Valuation ($) 2.7 b | Valuation ($) 7.4 m | Valuation ($) 2.8 b | Valuation ($) 11.1 b |
Twitter followers | Twitter followers 4.4 k | Twitter followers 10.6 k | Twitter followers 3.3 k | Twitter followers 1.5 k | Twitter followers 16.3 k | Twitter followers N/A | Twitter followers N/A | Twitter followers 9.3 k | Twitter followers 5 k |
Number of tweets (last 30 days) | Number of tweets (last 30 days) 5 | Number of tweets (last 30 days) 8 | Number of tweets (last 30 days) 4 | Number of tweets (last 30 days) 10 | Number of tweets (last 30 days) 23 | Number of tweets (last 30 days) N/A | Number of tweets (last 30 days) N/A | Number of tweets (last 30 days) 7 | Number of tweets (last 30 days) 13 |
Average likes per tweet (last 30 days) | Average likes per tweet (last 30 days) 4 | Average likes per tweet (last 30 days) 5.1 | Average likes per tweet (last 30 days) 36 | Average likes per tweet (last 30 days) 3.4 | Average likes per tweet (last 30 days) 3 | Average likes per tweet (last 30 days) N/A | Average likes per tweet (last 30 days) N/A | Average likes per tweet (last 30 days) 23.3 | Average likes per tweet (last 30 days) 40.6 |
Percentage of tweets with engagement (last 30 days) | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) 75% | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) 60% | Percentage of tweets with engagement (last 30 days) 86.96% | Percentage of tweets with engagement (last 30 days) N/A | Percentage of tweets with engagement (last 30 days) N/A | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) 69.23% |
Employee Rating | Employee Rating 3.6 | Employee Rating 3.6 | Employee Rating 3.9 | Employee Rating 3.6 | Employee Rating 4.2 | Employee Rating 4.3 | Employee Rating 2.1 | Employee Rating 4 | Employee Rating 4.1 |
Financial | |||||||||
Revenue (est.) | Revenue (est.) $587.4m (FY, 2022) | Revenue (est.) $3.6m (FY, 2022) | Revenue (est.) $243.2m (FY, 2022) | Revenue (est.) $2.2m (FY, 2022) | Revenue (est.) $1b (FY, 2022) | Revenue (est.) $363.3m (FY, 2022) | Revenue (est.) $340.6m (FY, 2022) | Revenue (est.) $52.1m (FY, 2022) | Revenue (est.) $933m (FY, 2022) |
Cost of goods | Cost of goods $14.1m (FY, 2022) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $140.2m (FY, 2022) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $573.3m (FY, 2022) | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit $897.2m (FY, 2022) | Gross profit N/A | Gross profit $33.2m (FY, 2022) | Gross profit N/A | Gross profit N/A |
Net income | Net income ($269.7m) (FY, 2022) | Net income ($266.6m) (FY, 2022) | Net income ($176.5m) (FY, 2022) | Net income ($311.9m) (FY, 2022) | Net income ($1.1b) (FY, 2022) | Net income ($707.4m) (FY, 2022) | Net income ($231.6m) (FY, 2022) | Net income ($474.2m) (FY, 2022) | Net income ($703.5m) (FY, 2022) |
Operating ⚠ | |||||||||
Patents Issued | Patents Issued N/A | Patents Issued N/A | Patents Issued 359 (FY, 2016) | Patents Issued 240 (FY, 2016) | Patents Issued N/A | Patents Issued N/A | Patents Issued N/A | Patents Issued N/A | Patents Issued N/A |
Phase I Trials Products | Phase I Trials Products 6 (FY, 2020) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 2 (FY, 2016) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A |
Phase II Trials Products | Phase II Trials Products 24 (FY, 2020) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 4 (FY, 2016) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A |
Phase III Trials Products | Phase III Trials Products 6 (FY, 2020) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 1 (FY, 2016) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A |
Funding | |||||||||
Total funding raised | Total funding raised N/A | Total funding raised $ 409m | Total funding raised $ 147.1m | Total funding raised $ 468.9m | Total funding raised $ 1.5b | Total funding raised $ 200.1m | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A |
Bluebird Bio is a developer of gene therapies for severe genetic diseases and cancer.
View companyArrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.
View companyReata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases.
View companyAlnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi.
View company